Drugs moving into the clinic: 38

The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.

Stem cell product given to patients immediately after haemorrhagic stroke

LifeCycle Pharma

LCP-Siro (sirolimus/ rapamycin)

Immune - prevention of organ rejection

Sirolimus or rapamycin is an imunosuppressant (marketed by Wyeth as Rapamune). It binds to FK-binding protein 12 (FKBP12) and then to mammalian target of rapamycin (mTOR) complex 1. This limits the response to interleukin-2 (IL-2) and therefore blocks activation of T and B cells. Product is new formulation to try and achieve increased bioavailability and reduced dosing.

This content is copyright protected

The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.